Genzyme Spinning Off Surgical Division, Transferring NeuroCell In-House
This article was originally published in The Gray Sheet
Executive Summary
Genzyme General plans to spin off its surgical products business into a separately traded company by the third quarter of 1999 in order to accelerate growth in both businesses, the Cambridge, Massachusetts-based firm announced March 4 in reporting 1998 year-end results.
You may also be interested in...
TheraCyte Cell Encapsulation System IDE Slated For Second Quarter
TheraCyte, Inc. plans to file an investigational device exemption with FDA during the second quarter for a Phase I study intended to evaluate the TheraCyte encapsulated cell technology implant system.
Genzyme Biosurgery To Include Tissue Repair/Surgical Units, Biomatrix
Genzyme Tissue Repair's 26-person Carticel sales force could aid Biomatrix' marketing efforts for Synvisc following the merger of Genzyme Surgical Products, Genzyme Tissue Repair and Biomatrix to create a new company, Genzyme Biosurgery.
TheraCyte Cell Encapsulation System IDE Slated For Second Quarter
TheraCyte, Inc. plans to file an investigational device exemption with FDA during the second quarter for a Phase I study intended to evaluate the TheraCyte encapsulated cell technology implant system.